Dual specificity phosphatase 6 (DUSP6)

Dual specificity phosphatase 6 (DUSP6), also known as MKP3, is a cytosolic enzyme that acts as a highly specific negative feedback regulator of the mitogen-activated protein kinase (MAPK) signaling pathway, particularly by dephosphorylating and inactivating ERK1 and ERK2 (UniProt Q16828; NIH PMC3706763). DUSP6 mRNA expression is directly induced by the ERK pathway, making it a reliable biomarker for MAPK pathway activation in various cancers, including lung and thyroid carcinomas (PubMed 28915247; NIH PMC2825218). In many malignancies, such as glioblastoma and thyroid carcinoma, DUSP6 acts as a pro-oncogenic factor that promotes tumor cell survival and chemoresistance, whereas in other contexts like pancreatic cancer, it may function as a tumor suppressor (PubMed 23838916; NIH PMC5593310). Therapeutic strategies targeting DUSP6 include small molecule allosteric inhibitors like BCI and RNA-based approaches such as siRNA or antisense oligonucleotides to reduce DUSP6 mRNA levels (PubMed 19194483; NIH PMC10504144). Modulating DUSP6 activity or expression aims to sensitize cancer cells to chemotherapy and targeted inhibitors, although its context-dependent roles present challenges for broad clinical application (PubMed 23838916).

Other names

MKP3PYST1Mitogen-activated protein kinase phosphatase 3Dual specificity protein phosphatase 6

Allosteric inhibition of the phosphatase catalytic activity or RNA interference-mediated knockdown of mRNA transcripts to prevent protein synthesis.